rilescat – Healthtechnica

February 25, 2026

From Idea to Impact: How the BISBLOX DNA Brings Health Technology to Market

There is no shortage of good ideas in health care.

There are AI-powered diagnostic tools that can spot cancer earlier than radiologists. Remote monitoring platforms that promise to keep seniors out of hospitals. Software as a medical device (SaMD) products that claim to reshape cardiology, neurology, behavioral health. Every week, another founder steps onto a stage, slides glowing behind them, and announces a breakthrough that will “change everything.”

And yet, most of these breakthroughs never reach the patient.

Not because the science is flawed. Not because the technology fails. But because bringing health technology to market is less like building an app and more like navigating a labyrinth — regulatory hurdles, reimbursement complexity, procurement politics, clinical validation, cybersecurity requirements, capital constraints, and cultural resistance within health systems.

It is here, in this messy middle, that many promising health technologies stall.

The BISBLOX DNA framework was built precisely for this terrain.

At its core, the BISBLOX DNA is not a pitch deck template or a surface-level checklist. It is a disciplined diagnostic model that examines a company through six interdependent lenses: Product, Technology, Market, Financials, Team, and Needs. In health technology, where risk tolerance is low and consequences are high, this structured clarity can mean the difference between a promising idea and a scalable solution.

The Product: From Innovation to Clinical Reality

Health technology founders often fall in love with the elegance of their innovation. But hospitals and regulators are not buying elegance. They are buying outcomes, safety, and integration.

The first question the BISBLOX DNA asks is not “Is this innovative?” but “Does this solve a defined clinical problem in a measurable way?”

A health product must move beyond novelty. It must answer:

What clinical pain point does it resolve?
How does it improve outcomes compared to the standard of care?
Is it additive to clinician workflows or disruptive to them?
Does it fit inside existing reimbursement models?

In many cases, companies discover that their product is technically brilliant but clinically misaligned. The BISBLOX DNA surfaces this early — before millions are spent on development or marketing.

This matters particularly in regulated pathways such as FDA 510(k) or De Novo clearances for software-based medical technologies. A product that is not tightly scoped to a defined use case risks extended review cycles, additional clinical studies, and ballooning costs.

Clarity at the Product level is not cosmetic. It is survival.

The Technology: Security, Scalability, and Trust

Health care is now inseparable from cybersecurity.

A single breach can halt hospital operations, expose patient records, and destroy trust. As artificial intelligence systems are increasingly embedded in diagnostic and decision-making workflows, cybersecurity is no longer a technical afterthought. It is a regulatory and ethical mandate.

The BISBLOX DNA evaluates:

Is the architecture secure by design?
Does it align with modern cybersecurity frameworks?
Can it scale across multiple health systems?
Is it interoperable with EHRs and legacy infrastructure?

In an era where AI-driven tools are proliferating, the question is not whether the algorithm works in a lab environment. It is whether it works securely in a hospital environment.

Health systems will not risk patient data — or their reputations — for a startup that treats cybersecurity as an optional feature.

The DNA framework forces this conversation early. It asks uncomfortable questions about infrastructure resilience, compliance readiness, and long-term scalability. For many founders, it is the first time these questions are confronted head-on.

And it is far less expensive to redesign architecture before deployment than after a breach.

The Market: Who Actually Buys This?

Health care purchasing decisions are famously complex.

The clinician may love the product. The CIO may worry about integration. The CFO may ask about reimbursement. The compliance officer may question regulatory exposure. Procurement may require a 12-month vendor approval cycle.

Too often, health technology companies define their “market” as “hospitals” or “providers.” The BISBLOX DNA dissects this further:

Who is the economic buyer?
Who is the clinical champion?
Who can silently block the deal?
How does procurement actually move within this segment?

Understanding market topography is not optional. It is foundational.

For example, a remote patient monitoring solution may assume hospitals are the target customer. But in reality, value-based care organizations, insurers, or large multi-specialty physician groups may be more aligned buyers. The wrong market entry strategy can cost years.

The BISBLOX DNA pushes founders to map influence structures, funding sources, and stakeholder motivations. In health technology, decisions are rarely made by a single executive. They are made through layers of risk assessment and institutional memory.

Precision in Market strategy accelerates adoption and reduces wasted effort.

The Financials: Beyond the Funding Round

In venture-backed health technology, the conversation often centers on runway and valuation.

But the DNA framework shifts the focus to sustainability.

What is the true cost of regulatory compliance?
What are the unit economics at scale?
How long is the average sales cycle?
What capital is required before breakeven?
Is the pricing aligned with reimbursement realities?

Health technology companies frequently underestimate time-to-revenue. Sales cycles can stretch 12 to 24 months. Regulatory timelines can expand unexpectedly. Clinical studies can require additional capital.

The BISBLOX DNA introduces financial realism.

It aligns projections with actual market dynamics. It tests whether pricing strategies match the purchasing psychology of health systems. It examines whether the company can survive the “long middle” between product development and scaled revenue.

In health care, optimism without financial discipline is dangerous.

The Team: Can They Carry the Weight?

In health technology, the team must bridge two worlds: clinical credibility and technical excellence.

A brilliant engineering team without regulatory experience may falter. A strong clinical advisory board without operational leadership may stall execution.

The DNA framework assesses:

Does the team have regulatory fluency?
Is there real-world clinical experience embedded?
Does leadership understand health system politics?
Is there operational depth to scale?

Health technology is not simply a product challenge. It is a trust challenge.

Hospitals want to know that the team behind the product understands patient safety, compliance, and clinical workflows. They want to know that the company will still exist five years from now.

A capable team de-risks adoption.

The BISBLOX DNA identifies gaps — not to criticize, but to strengthen. It may recommend adding regulatory advisors, strengthening cybersecurity leadership, or aligning with strategic health partners.

In health care, credibility is currency.

The Needs: What Is Missing — and Why It Matters

The final lens of the DNA is often the most revealing.

What does the company not yet have?

Strategic partnerships?
Distribution channels?
Clinical validation data?
Capital depth?
Executive discipline?

This is where optimism meets reality.

Health technology companies frequently focus on what they have built. The DNA focuses on what must be built next. It clarifies the gap between current state and scalable market presence.

Sometimes the missing element is not capital, but clarity. Sometimes it is not technology, but regulatory navigation. Sometimes it is not product-market fit, but sales execution discipline.

By identifying needs explicitly, the DNA transforms ambiguity into an actionable roadmap.

Artificial Intelligence and the New Complexity

Artificial intelligence has accelerated both opportunity and risk.

AI can now assist in diagnostics, triage, imaging interpretation, predictive modeling. It can personalize treatment plans and detect anomalies invisible to human analysis.

But AI in health care introduces additional scrutiny:

Algorithmic bias.
Explainability requirements.
Data provenance.
Continuous model monitoring.
Cybersecurity vulnerabilities.

Regulators and hospital boards are increasingly cautious. They want to understand not only what the AI does, but how it does it — and how it can fail safely.

The BISBLOX DNA integrates these considerations across Product, Technology, and Market. It ensures AI-driven health technologies are not merely innovative but deployable.

Innovation without governance will not scale in health care.

From Diagnosis to Deployment

The name “DNA” is deliberate.

In biology, DNA encodes structure and potential. But potential alone does not guarantee expression. Conditions must align. Signals must activate.

In business, the same is true.

The BISBLOX DNA does not promise shortcuts. It does not pretend that health care is easy. Instead, it offers disciplined clarity in an environment defined by complexity.

It moves companies from abstract enthusiasm to structured readiness.

For some, the process confirms strength and accelerates go-to-market execution. For others, it surfaces hard truths — misaligned markets, underestimated regulatory burdens, fragile financial assumptions. Those revelations can be uncomfortable. But they are far less painful than public failure.

Health technology does not fail because founders lack vision. It fails because systems are unforgiving.

A structured diagnostic approach transforms vision into viability.

The Stakes Are Higher in Health Care

When a consumer app fails, users delete it.

When a health technology fails, consequences can ripple across patients, clinicians, and institutions.

The margin for error is thinner.

This is why disciplined frameworks matter. Not as bureaucratic exercises, but as guardrails.

The BISBLOX DNA brings together strategic assessment, regulatory awareness, cybersecurity rigor, market mapping, and operational clarity. It does not replace clinical trials or regulatory approval. But it prepares companies for them.

In a world increasingly shaped by artificial intelligence and digital health platforms, the demand for trustworthy, secure, scalable health technology will only grow.

Bringing those technologies to market will require more than invention. It will require navigation.

And navigation begins with knowing precisely where you stand.

The BISBLOX DNA provides that starting point — a clear-eyed diagnosis of a company’s strengths, vulnerabilities, and next steps. For health technology founders determined to move beyond promise and into impact, that clarity may be the most valuable innovation of all.

Learn more at BISBLOX.com

February 20, 2017

Palmetto Health Quality Collaborative Launches Caradigm Solutions to Support Population Health Initiatives

Orlando, FL-HIMSS Conference 2017 – Feb 20, 2017 – Caradigm®, the leader in enterprise population health, today announced that the Palmetto Health Quality Collaborative (PHQC), the clinically integrated network affiliated with Palmetto Health is now live on Caradigm solutions to drive population health through its clinically integrated network. The PHQC has implemented the Caradigm Care Management and the Caradigm Intelligence Platform, and is working to deploy Caradigm Risk Management and Quality Improvement.

Palmetto Health is the largest and most comprehensive integrated health care system in the South Carolina Midlands region and its clinically integrated network, the Palmetto Health Quality Collaborative, has over 1,200 participating providers. Caradigm Care Management supports the PHQC’s interdisciplinary care teams in sharing patient information, streamlining time-consuming workflows, and ensuring all members of the care delivery team are able to work at the top of their license. With these improvements, the care teams will be better able to transition high-risk patients moving from inpatient or Emergency Department care back into the community or to a patient-centered medical home. The PHQC participates in a variety of value-based population health initiatives including a Medicare Shared Savings Program, commercial ACO products, and the management of the Palmetto Health self-insured employee population.

Continue reading “Palmetto Health Quality Collaborative Launches Caradigm Solutions to Support Population Health Initiatives”

February 16, 2017

Health Spending Growth Projections, 2016–25

Bethesda, MD—New estimates released today from the Office of the Actuary at the Centers for Medicare and Medicaid Services (CMS) project an average rate of national health spending growth of 5.6 percent for 2016–25, outpacing average projected growth in gross domestic product (GDP) by 1.2 percentage points. As a result, the health share of the economy is projected to climb to 19.9 percent by 2025—up from 17.8 percent in 2015. These projections are constructed using a current-law framework and do not assume potential legislative changes over the projection period.

Growth in national health spending is expected to be driven by projected increases in medical prices from a recent historic low of 0.8 percent in 2015, to nearly 3.0 percent by 2025. Growth in the use and intensity of medical services, however, is projected to slow relative to that experienced in 2014 and 2105, as the impacts of the Affordable Care Act’s coverage expansion wane and enrollment growth in Medicaid and private insurance slows. Changes in the age and sex distribution of the population are projected to consistently put upward pressure on growth throughout the projection period, contributing an average of about 0.5 percentage point to growth per year.

Every year the CMS Office of the Actuary releases an analysis of how Americans are expected to spend their health care dollars in the years ahead. The projected average growth rate for 2016-25 (5.6 percent) reflects the latest expectations from the Office of the Actuary and updates its 2016 report, published last year in Health Affairs.

The new findings appear as a Health Affairs Web First article; the study link will be:

http://content.healthaffairs.org/lookup/doi/10.1377/hlthaff.2016.1627

The study will also be published in the journal’s March 2017 issue, to be released Monday, March 6, at 4:00 p.m. ET.

“After an anticipated slowdown in health spending growth for 2016, we expect health spending growth to gradually increase as a result of faster projected growth in medical prices that is only partially offset by slower projected growth in the use and intensity of medical goods and services,” says Sean Keehan, the study’s first author. “Irrespective of any changes in law, it is expected that because of continued cost pressures associated with paying for health care, employers, insurers, and other payers will continue to pursue strategies that seek to effectively manage the use and cost of health care goods and services.”

The first two years of the projection period are expected to have the slowest health spending growth rates (4.8 percent in 2016 and 5.4 in 2017), as Medicaid and private health insurance spending growth slow and Medicare spending growth remains low. For 2018 and beyond, Medicare and Medicaid expenditures are expected to grow faster than in the 2016-17 period, and more rapidly than private health insurance spending. Keehan and his coauthors site several reasons for this. First, the use of Medicare services is expected to increase from its recent historical lows. Second, the Medicaid population mix will trend more toward older, sicker, and more costly beneficiaries. Third, baby boomers will continue to age into Medicare, with some dropping private insurance as a result. And finally, growth in the demand for health care for those with private insurance is expected to slow as enrollees face gradually rising relative health care prices and slowing income growth.

Here is a chronological look at projected trends, based on the current-law framework:

2016

National health spending is projected to have grown 4.8 percent in 2016, compared to 5.8 percent in 2015, and to have reached nearly $3.4 trillion dollars.
The uninsured population is expected to have declined again in 2016, by 1.2 million (to 28 million), driven primarily by increases in the numbers of people with employer-sponsored insurance and Medicaid.
Medicaid spending growth is expected to have greatly decelerated, from 9.7 percent in 2015 to just 3.7 percent in 2016, driven in part by the expectation of slower enrollment growth. In contrast, Medicare spending growth is projected to have accelerated, but to have remained low relative to its historical average growth (reaching 5.0 percent in 2016, up from 4.5 percent in 2015).
The largest projected slowdown in 2016 among the major goods and services sectors is prescription drug spending, which is projected to have grown just 5.0 percent in 2016, down from 9.0 percent in 2015. This slowdown can largely be attributed to the decrease in use of drugs to treat hepatitis C.

2017

National health spending growth is projected to accelerate to 5.4 percent in 2017, up from 4.8 percent in 2016.
From a payer perspective, Medicare spending growth is projected to accelerate in 2017 to 5.9 percent (from 5.0 percent in 2016), due to spending associated with physician and clinical services and hospital services for Medicare beneficiaries.
Private health insurance spending growth is also expected to accelerate, to 6.5 percent in 2017 up from 5.9 percent in 2016, in large part because of premium growth for Marketplace plans due to underpricing of premiums in past years and the elimination of risk corridor payments.

2018–19

National health spending growth is projected to accelerate from 5.4 percent in 2017 to an average of 5.9 percent for 2018–19, driven primarily by faster growth in Medicare and Medicaid.
Medicare spending is expected to average 7.1 percent for 2018–19 (up from 5.9 percent in 2017), with the expectation that the use and intensity of medical services will increase to rates that are more consistent with Medicare’s longer-term historical experience. As a result, Medicare per enrollee average spending growth is projected to increase from 3.0 percent in 2017 to an average of 4.1 percent in 2018–19.
Medicaid spending growth is also projected to accelerate—largely due to projected growth in the use and intensity of care needed for Medicaid’s increasingly larger proportion of older and disabled enrollees (up from 3.7 percent projected increase in 2017 to an expected average of 5.9 percent for 2018–19).
Prescription drug spending growth is anticipated to accelerate from 5.7 percent in 2017 to an average of 7.0 percent for 2018–19, driven by faster price growth as a result of fewer brand-name drugs losing patent protection.

2020–25

During 2020–25, national health expenditure growth is projected to rise at an average rate of 5.8 percent, similar to the average growth rate for 2018–19 of 5.9 percent, and still more rapidly than growth in GDP. These trends result in a projected increase in the health share of the economy to 19.9 percent in 2025.
Medicare spending is projected to grow at an average rate of 7.6 percent in 2020–25 due to strong enrollment growth from baby boomers and the aging of the existing Medicare population.
Average growth in Medicaid spending for this period (5.9 percent) is similar to that projected for 2018–19 and roughly the same as total health spending growth.
Private health insurance spending growth is expected to decelerate (from 5.7 percent for 2018–19 to 5.0 percent for 2020–25), in a lagged response to slower growth in disposable personal income toward the end of the projection period and the expected implementation of the excise tax on high-cost insurance plans starting in 2020.
Average annual medical price growth is projected to gradually rise, from 2.4 percent for 2018–19 to 2.7 percent for 2020–25.
By 2025, 47 percent of health spending is projected to be sponsored by federal, state, and local governments, up from 46 percent in 2015. This expected higher share of spending by governments reflects, in part, the continued transition of the baby-boomer generation into Medicare. In contrast, the projected share of health spending sponsored by businesses and households in 2025 is expected to fall one percentage point, from 54 percent in 2015 to 53 percent in 2025.

January 13, 2017

AVALERE EXPERTS PREDICT 2017 TO BE A YEAR OF SIGNIFICANT CHANGE ACROSS THE HEALTHCARE SPECTRUM

This year will be the start of major environmental changes for the healthcare industry following a shift in the balance of power in Washington, D.C. and the states. Avalere experts anticipate repeal of the Affordable Care Act (ACA) along with broader efforts to restructure entitlement programs, which introduces the potential for a range of new tax and other programmatic ideas.

At the same time, Avalere experts expect a continuation of many existing trends — including, most importantly, the shift from volume to value in healthcare markets. This shift will position providers in the center of healthcare change, leading to increased demands for data and a growing role for quality measurement in payment systems.

A focus on the consumer is also a major facet of the environment that deserves attention. Digital health technology will increasingly place the consumer at the center of decision making and change the way patients access healthcare. At the same time, lower-cost insurance benefit designs with higher out-of-pocket costs, more limited access to drugs, and narrower provider networks will continue to spread.

Avalere experts are looking at 10 specific trends in 2017:

Election Results Will Directly Affect Insurance Coverage: In addition to the repeal of the ACA, Avalere experts predict the new Congress and Administration will look to make changes to the Medicare and Medicaid programs, including ways to cap spending, put more control in the hands of states, and increase the role of private plans in the programs.
Costs of Employer Benefits Continue to Be Shifted to Workers: As employer-sponsored plans take on the benefit innovations adopted by the ACA marketplaces (e.g., narrow networks, higher out-of-pocket costs, limited formularies) to achieve lower premiums, the consumer is put at the center of the healthcare purchasing decision and exposed to more of the costs. Avalere experts predict this could shift employee behavior to choose lower-premium health plans, seek care from lower-cost providers, or forgo services.
Drug Pricing Threat Diminished but Not Forgotten: Avalere experts predict market-driven approaches will be enacted in the context of entitlement reform, or via other means, as a way to curb high drug prices. These could include policies that emphasize outcomes-based contracts, reforms to the Food and Drug Administration (FDA), or ways to increase transparency in the system.
Payers Respond to Biosimilar Market Competition: In 2017, according to Avalere experts, payers will need to determine whether they will substitute biosmilars for innovator products, as more biosimilars are approved by the FDA and become commercially available, or rely on competition to drive price discounts across all types of prescription drugs.
Outcomes-Based Contracting Shapes Drug Purchasing: Experts from Avalere predict that, amidst concerns about drug prices, outcomes-based contracts between manufacturers, payers, and providers could be used as a market-based solution to address drug costs and improving patient outcomes in 2017.
Value-Based Payment Becoming a Reality: The move toward value-based payment will continue in 2017 as more public and private payers adopt these models across more conditions and provider types, according to Avalere experts. Value-based care models enjoy bipartisan support. Furthermore, the Center for Medicare and Medicaid Innovation is testing value and delivery reform across 46 programs, and there are over 800 Accountable Care Organizations nationwide.
Proliferation of Quality Measures: The existing measure development process is slow and costly, and as a result, measurement gaps remain for certain diseases, care settings, and patient-reported outcomes. Experts from Avalere predict the U.S. could experience a rapid proliferation of measures via the Medicare Quality Payment Program’s qualified clinical data registries.
New Care Models Demand Optimal Use of Post-Acute Care: According to Avalere experts, new care models will focus on improving post-acute care for patients recently discharged from the hospital—a major driver of healthcare spending. In 2017, payers and providers may seek to optimize post-acute care patterns to improve outcomes, reduce readmissions, and lower overall costs.
Value Frameworks Must Evolve to Encourage Adoption: According to Avalere experts, value frameworks could be used to inform decision making by patients and providers, and to assess coverage in health plans; however, they have had limited impact to date. Improvements in transparency and the inclusion of the patient’s voice in models could spur their adoption in 2017.
Digital Health Is Transforming Patient Engagement: Innovations like web-based coaching, cloud-based self-management programs, real-time monitoring, and online urgent care clinics are transforming how care is delivered and how patients engage in the healthcare system. In 2017, these innovations will move from the testing phase and be scaled out in an effort to improve care while lowering costs, according to experts at Avalere.

January 6, 2017

WordPress Resources at SiteGround

WordPress is an award-winning web software, used by millions of webmasters worldwide for building their website or blog. SiteGround is proud to host this particular WordPress installation and provide users with multiple resources to facilitate the management of their WP websites:

Expert WordPress Hosting

SiteGround provides superior WordPress hosting focused on speed, security and customer service. We take care of WordPress sites security with unique server-level customizations, WP auto-updates, and daily backups. We make them faster by regularly upgrading our hardware, offering free CDN with Railgun and developing our SuperCacher that speeds sites up to 100 times! And last but not least, we provide real WordPress help 24/7! Learn more about SiteGround WordPress hosting

WordPress tutorial and knowledgebase articles

WordPress is considered an easy to work with software. Yet, if you are a beginner you might need some help, or you might be looking for tweaks that do not come naturally even to more advanced users. SiteGround WordPress tutorial includes installation and theme change instructions, management of WordPress plugins, manual upgrade and backup creation, and more. If you are looking for a more rare setup or modification, you may visit SiteGround Knowledgebase.

Free WordPress themes

SiteGround experts not only develop various solutions for WordPress sites, but also create unique designs that you could download for free. SiteGround WordPress themes are easy to customize for the particular use of the webmaster.